Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > generic: None

& halflife

: ~12 hours

or ~27 days

Use the filters below to narrow your results.

Belsomra (1) · Emgality (1) · Vyepti (1)

Anti-CGRP ligand monoclonal antibody (2) · Dual orexin receptor antagonist (DORA) (1) · the first approved (1)

Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) · Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)

Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · Preventive treatment of migraine in adults (1) · Preventive treatment of migraine in adults; episodic cluster headache (1)

10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)

100 mg/mL vial for IV infusion (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1)

20 mg/d (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 300 mg/quarter (1)

Intravenous infusion (1) · Oral (1) · Subcutaneous (1)

Effect demonstrated within 24 hours in some patients (1) · Over weeks (1) · ~30 min (1)

3-month dosing interval (1) · Monthly dosing (1) · ~7-8 hours (1)

100% (IV) (1) · Not formally established (high SC) (1) · ~82% (1)

Limited data; avoid (3)

Rx (2) · Rx, Schedule IV (US) (1)

Showing below up to 3 results in range #1 to #3.

E

Eptinezumab

G

Galcanezumab

S

Suvorexant

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"